Catalog No.
RHH72401
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400
Target
VSTM3, TIGIT, V-set and transmembrane domain-containing protein 3, VSIG9, V-set and immunoglobulin domain-containing protein 9, T-cell immunoreceptor with Ig and ITIM domains
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q495A1
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3U77
Impact of immune checkpoint TIGIT on the activation and function of natural killer cells in rheumatoid arthritis patients., PMID:40465407
Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9., PMID:40445384
NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells., PMID:40421025
Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy., PMID:40415479
Adjuvant Immunotherapy in Microsatellite Instability-High Colon Cancer: A Literature Review on Efficacy, Challenges, and Future Directions., PMID:40415356
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer., PMID:40411966
TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory., PMID:40394151
NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors., PMID:40392373
Potential Roles of Serum Exosomal CD155 and its Impact on NK Cell Immunosuppression in Hepatocellular Carcinoma., PMID:40326845
Tph cells are expanded in IgA vasculitis nephritis., PMID:40315784
Influence of polyfunctional Tbet+ T cells on specific clinical events in chronic lymphocytic leukaemia., PMID:40313965
Current Status and Future Prospects of Immune Checkpoint Inhibitors Research in the Treatment of Multiple Myeloma., PMID:40304327
Immuno-PET Imaging of a 68Ga-Labeled Single-Domain Antibody for Detecting Tumor TIGIT Expression., PMID:40298304
T-cell immunoglobulin and ITIM domain as a target in combo anti-PD-(L)1 cancer therapy., PMID:40294684
Identification and characterization of tissue resident memory T cells in malignant pleural effusions associated with non-small cell lung cancer., PMID:40285480
UCN expresses differently in left-sided and right-sided colon cancer contributing to distinct immune microenvironment via regulating CCL23., PMID:40274491
Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications., PMID:40243372
Targeting the poliovirus receptor to activate T cells and induce myeloid-derived suppressor cells to differentiate to pro-inflammatory macrophages via the IFN-γ-p-STAT1-IRF8 axis in cancer therapy., PMID:40229462
Anti-TIGIT inhibitors plus PD-1 or PD-L1 inhibitors versus PD-1 or PD-L1 inhibitors for first-line treatment of advanced non-small cell lung cancer., PMID:40226904
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis., PMID:40214505
Pinpointing potent hits for cancer immunotherapy targeting the TIGIT/PVR pathway using the XGBoost model, centroid-based virtual screening, and MD simulation., PMID:40194343
Computational screening for natural compounds as potential immune checkpoint inhibitors against TIGIT, a new avenue in cancer immunotherapy., PMID:40163147
Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers., PMID:40159541
Management of metastatic melanoma with combinations including PD-1 inhibitors., PMID:40159098
Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer., PMID:40152219
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II study., PMID:40147985
AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies., PMID:40134430
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment., PMID:40111422
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies., PMID:40075753
Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes., PMID:40073269
Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+ T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment., PMID:40010766
The past, the present and the future of immune checkpoints inhibitors in multiple myeloma., PMID:39987500
Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and CD155/TIGIT Pathway., PMID:39975177
Whole-Component Antigen Nanovaccines Combined With aTIGIT for Enhanced Innate and Adaptive Anti-tumor Immunity., PMID:39967373
TIGIT expression in extrahepatic cholangiocarcinoma and its impact on CD8 + T cell exhaustion: implications for immunotherapy., PMID:39939322
TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial., PMID:39929671
Model-Informed Selection of the Recommended Phase 2 Dosage for Anti-TIGIT Immunotherapy Leveraging co-Expressed PD-1 Inhibitor Target Engagement., PMID:39921877
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study., PMID:39855251
Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity., PMID:39851063
Exploring novel immunotherapy in advanced esophageal squamous cell carcinoma: Is targeting TIGIT an answer?, PMID:39847233
Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression., PMID:39838375
The Role of YY1 in the Regulation of LAG-3 Expression in CD8 T Cells and Immune Evasion in Cancer: Therapeutic Implications., PMID:39796650
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial., PMID:39775043
Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?, PMID:39771968
Enhancement of Human Immunodeficiency Virus-Specific CD8+ T Cell Responses with TIGIT Blockade Involves Trogocytosis., PMID:39770396
VISTA in hematological malignancies: a review of the literature., PMID:39742253
Regulatory T cell therapy is associated with distinct immune regulatory lymphocytic infiltrates in kidney transplants., PMID:39731908
TIGIT+ CD4+ regulatory T cells enhance PD-1 expression on CD8+ T cells and promote tumor growth in a murine ovarian cancer model., PMID:39707532
In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors., PMID:39690741
Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice., PMID:39673995
For research use only. Not for human or drug use.
